824 results on '"Koch, Michael O."'
Search Results
52. RANDOMIZED CLINICAL TRIAL EXAMINING THE RETURN OF EARLY URINARY CONTINENCE AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY WITH OR WITHOUT A BLADDER NECK SLING: MP37-11
53. Barriers to Single-Dose Intravesical Chemotherapy in Nonmuscle Invasive Bladder Cancer—What's the Problem?
54. Lymph node-positive bladder cancer: surgical, pathologic, molecular and prognostic aspects
55. Oncologic and quality-of-life outcomes with wide resection in robot-assisted laparoscopic radical prostatectomy
56. Contemporary bladder cancer: Variant histology may be a significant driver of disease
57. Lymph node metastases in patients with urothelial carcinoma variants: Influence of the specific variant on nodal histology
58. Randomized, Controlled Trial of Spaced Education to Urology Residents in the United States and Canada
59. Phase I/II Trial of High Intensity Focused Ultrasound for the Treatment of Previously Untreated Localized Prostate Cancer
60. Thermal-based treatment options for localized prostate cancer
61. Is the PSA Era Over?
62. High-Intensity Focused Ultrasound for the Treatment of Prostate Cancer
63. Contributors
64. PD45-09 IDENTIFYING SITES OF PROSTATE CANCER RECURRENCE IN 68Ga-PSMA PET/CT BASED ON SCAN INDICATION.
65. Ranking Important Factors for Using Postoperative Chemotherapy in Nonmuscle Invasive Bladder Cancer: Conjoint Analysis Results From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
66. Dyslipidemia, statins and prostate cancer
67. Pathological characterization of unifocal prostate cancers in whole-mount radical prostatectomy specimens
68. Elevated Expression of Cancer-Associated Proliferating Cell Nuclear Antigen in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer
69. Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.
70. Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188.
71. Robotic and open partial nephrectomy for intermediate and high complexity tumors: a matched-pairs comparison of surgical outcomes at a single institution
72. Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma
73. Robot-Assisted Radical Prostatectomy in Patients with a History of Holmium Laser Enucleation of the Prostate: The Indiana University Experience
74. Robotic and open partial nephrectomy for tumors in a solitary kidney
75. Prostate Specific Membrane Antigen Targeted Positron Emission Tomography of Primary Prostate Cancer: Assessing Accuracy with Whole Mount Pathology
76. Should the Patient With Positive Margins After Radical Prostatectomy Receive Adjuvant Radiation?
77. The origins of urothelial carcinoma
78. Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high-grade prostate cancer
79. Anatomic distribution and pathologic characterization of small-volume prostate cancer (
80. Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer
81. Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations
82. Use of Ileum as Ureteral Replacement in Urological Reconstruction
83. c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications
84. Prostate Cancer Therapy with High-Intensity Focused Ultrasound
85. Does wide primary perirectal dissection during radical retropubic prostatectomy alter pathologic and biochemical outcomes?
86. LYMPHOVASCULAR INVASION IS AN INDEPENDENT PROGNOSTIC FACTOR IN PROSTATIC ADENOCARCINOMA
87. PREOPERATIVE PREDICTION OF SMALL VOLUME CANCER (LESS THAN 0.5 ML) IN RADICAL PROSTATECTOMY SPECIMENS
88. Focal Prostate Therapy
89. FACE AND CONSTRUCT VALIDATION OF A NOVEL VIRTUAL REALITY ROBOTIC SIMULATOR: 1920
90. ROBOTIC VS. OPEN RADICAL PROSTATECTOMY: A SINGLE INSTITUTION, SINGLE SURGEON COMPARISON OF OUTCOME: 1778
91. Re: Editorial Comments
92. Functional and Clinicopathologic Outcomes Using a Modified Vescica Ileale Padovana Technique
93. Positive Margins in Urological Oncology
94. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy
95. Tertiary Gleason Pattern 5 is a Powerful Predictor of Biochemical Relapse in Patients With Gleason Score 7 Prostatic Adenocarcinoma
96. Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?
97. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence
98. Is it necessary to separate clinical stage T1c from T2 prostate adenocarcinoma?
99. The Combined Percentage of Gleason Patterns 4 and 5 Is the Best Predictor of Cancer Progression After Radical Prostatectomy
100. Utility of the fourth arm to facilitate robot-assisted laparoscopic radical prostatectomy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.